media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

New At-Home Option for Alzheimer’s! Lecanemab Subcutaneous Auto-Injector Pen Approved in China | Approval Alert

Recently, China’s National Medical Products Administration (NMPA) approved the marketing of the anti-amyloid beta antibody drug lecanemab subcutaneous auto-injector pen for the treatment of early Alzheimer’s disease. This is the first and currently only anti-amyloid therapy in China that can be administered at home, making China the second country globally to approve this subcutaneous formulation. The at-home injection product is expected to be officially launched by the end of 2026 or early 2027. Lecanemab, jointly developed by Eisai and Biogen, is an anti-amyloid beta protofibril antibody that slows the progression of Alzheimer’s disease by clearing beta-amyloid deposits in the brain. Previously, the intravenous infusion formulation of lecanemab was already approved in China, requiring patients to regularly visit hospitals for infusion treatment. The newly approved subcutaneous auto-injector pen allows patients to self-inject at home, significantly improving medication convenience and patient adherence. Patients now have two administration route options: they can choose ...
- Source: drugdu
- 28
- September 8, 2026
Sinopharm Group and Hansoh Pharmaceutical Reach Strategic Cooperation, Launch Four Special Projects Including Broad Market, Medical Access, Retail, and DTP | Market News

On September 8, according to Sinopharm Group (01099.HK), Sinopharm Group and Hansoh Pharmaceutical (03692.HK) recently reached a strategic cooperation. Based on years of in-depth cooperation, and centered on the goals of deepening industry-commerce collaboration and empowering high-quality industrial development, the two parties signed a strategic cooperation agreement and simultaneously launched four special cooperation agreements covering broad market, medical access, retail, and DTP, promoting the upgrade of industry-commerce cooperation from traditional business docking to a full-chain, full-cycle strategic collaboration. This strategic cooperation covers four key directions: in the broad market, the two parties will jointly promote the penetration of Hansoh Pharmaceutical’s products to grassroots medical markets to improve drug accessibility; in medical access, they will collaborate to advance product access and clinical application in hospitals at all levels; in retail, they will strengthen cooperation in retail pharmacy channels to expand the out-of-hospital market; in DTP (Direct to Patient), they will establish ...
- Source: drugdu
- 26
- September 8, 2026
Hybio Pharmaceutical’s Subsidiary Obtains Registration Certificate for Carboprost Tromethamine Injection, Deemed Passed Consistency Evaluation | Approval Alert

On September 7, Hybio Pharmaceutical (300199.SZ) announced that its wholly-owned subsidiary Gansu Chengji Biopharmaceutical Co., Ltd. has recently received the “Drug Registration Certificate” for Carboprost Tromethamine Injection (Certificate No.: 2026S03186) issued by China’s National Medical Products Administration (NMPA), with the drug approval number Guo Yao Zhun Zi H20265776 and specification of 1ml:250μg (calculated as C₂₁H₃₆O₅). Carboprost Tromethamine Injection is a prostaglandin prescription drug, classified as chemical drug Class 4, mainly used for the treatment of postpartum hemorrhage caused by uterine atony. According to relevant review principles, the drug is deemed to have passed the generic drug quality and efficacy consistency evaluation upon market approval. Postpartum hemorrhage is the leading cause of maternal death worldwide, and carboprost tromethamine, as a first-line drug for treating atonic postpartum hemorrhage, has stable clinical demand. Hybio Pharmaceutical stated that this certificate enriches the company’s product pipeline in the obstetrics and gynecology field, will enhance the ...
- Source: drugdu
- 25
- September 8, 2026
First in China! Hualan Vaccine’s Novel Influenza mRNA Vaccine Approved for Clinical Trials | Clinical Progress

On September 7, Hualan Vaccine (301207.SZ) announced that it has received the “Drug Clinical Trial Approval Notice” for its novel influenza virus mRNA vaccine from China’s National Medical Products Administration (NMPA). The vaccine is classified as a preventive biological product Class 1.2, and is approved for clinical trials to prevent influenza caused by vaccine-related influenza virus strains. Hualan Vaccine becomes the first company in China to obtain implied clinical trial approval for a novel influenza mRNA vaccine. The vaccine adopts the mRNA technology route, delivering mRNA encoding influenza virus-related antigens to express corresponding antigens in vivo and induce immune responses. From CDE acceptance on June 22 to clinical approval, it took only two and a half months, significantly faster than traditional vaccines. There are currently no influenza mRNA vaccine products on the market in China. As a leading enterprise in China’s influenza vaccine sector, Hualan Vaccine’s quadrivalent influenza vaccine consistently ...
- Source: drugdu
- 25
- September 8, 2026
The “King of Medicine” in Guangdong sold for 56.6 billion yuan.

The period from 2016 to 2025 marks a decade of continuous reform in China’s pharmaceutical industry. Centralized procurement policies are reshaping the industry’s logic, and a wave of innovative drugs is surging forward. In this profound industrial transformation, Guangdong’s pharmaceutical companies have delivered a remarkable performance . the rise of Guangdong’s “King of Medicines” from the perspectives of enterprise and brand dimensions, based on the terminal sales data of Guangdong pharmaceutical companies and drug brands from 2016 to 2025, using data from Yaozhi Data . Note: The drugs mentioned in this article cover various types of drugs, including innovative drugs, generic drugs, and traditional Chinese medicines; sales data comes from Yaozhi Data; the sales figures are based on the sales performance of pharmaceutical companies registered in Guangdong (including 21 prefecture-level cities) across the country in terms of terminal sales (hospitals + retail + e-commerce channels). 01 The King of Pharmaceutical ...
- Source: drugdu
- 25
- September 8, 2026
Analytica Anacon India

Organiser：Messe München International Time：September 10th – 12th, 2026 Address：HITEX Exhibition Centre Izzat Nagar Hyderabad 500 032, A.P. Exhibition hall：Hyderabad International Trade Exposition Centre Product range: Analytical Technology: Analytical instruments and equipment, microscopes and optical imaging processing, spectroscopy and chromatography products Testing, Measurement and Quality Control: Industrial quality control, material property identification technology, material testing, pharmaceutical and industrial quality control Laboratory Equipment: Laboratory apparatus and equipment, laboratory data and archiving management equipment, chemicals, reagents and consumables Life Sciences and Testing & Measurement Technology: Bioanalysis, biochemical reagents and bioinformatics technology, laboratory testing and measurement supplies About Analytica Anacon India： Analytica Anacon India is the most influential exhibition for laboratory, analytical and biochemical technologies in India and South Asia. This initiative will make the Indian Laboratory and Biotechnology Exhibition the largest and most influential professional exhibition for the laboratory, analytical and biochemical technology industry in India and even the entire South ...
- Source: drugdu
- 36
- September 8, 2026
【EXPERT Q&A】For suppliers without mature export cases, what else can be written on the enterprise page?

Drugdu.com expert’s response: Many new suppliers on the platform get stuck on one question when completing their company profile page: “We don’t have many mature export cases yet, so is there nothing substantial to write in our company introduction?” This is especially true for enterprises in the API, excipient, pharmaceutical intermediate and medical device sectors. If they do not yet have stable overseas orders or representative clients, they can easily end up with a very empty and generic company page. Common generic lines include: “We are a professional supplier.” “We provide high quality products.” “We have competitive prices and good service.” These statements are not technically wrong, but overseas buyers can hardly tell exactly what the enterprise is capable of delivering after reading them. Not having mature export cases does not mean your company page has to be empty. When buyers visit a company page, they do not only look ...
- Source: drugdu
- 44
- September 7, 2026
【EXPERT Q&A】The quotation was sent out for three days without a reply. What else can be sent during the second follow-up?

Drugdu.com expert’s response: When doing pharmaceutical foreign trade, many suppliers have encountered this situation: A buyer sends an inquiry asking about products, specifications and prices. The sales team sorts out materials, checks costs, and sends out a quotation. After the email or WhatsApp message is sent, three days pass with no reply. At this point, many people will write their second follow-up like this: “Any update?” Or: “Have you checked our quotation?” These lines are not completely useless, but their effect is usually limited. There are many reasons why a buyer does not reply: they may still be comparing prices internally, waiting for confirmation from an end customer, feeling that some information is missing from the quotation, or contacting multiple suppliers at the same time. If the second follow-up only presses for a reply, the buyer has no new information to respond with, and the communication can easily come to a standstill. For the ...
- Source: drugdu
- 69
- September 4, 2026
The snoring of 1 billion people can finally be cured! The FDA has accepted the marketing application for a new oral drug for obstructive sleep apnea.

If all goes well, a new drug for snoring will be approved early next year, potentially becoming the world’s first landmark drug targeting the neuromuscular causes of snoring . In July, Phase III clinical data of AD109 , a new oral drug for obstructive sleep apnea ( OSA ), was published in the American Journal of Respiratory and Critical Care Medicine . The data showed that the apnea-hypopnea index (AHI) decreased by 44.1% after treatment , and the oxygen depletion index and blood oxygen saturation were improved, indicating a significant improvement in the severity of OSA. picture AD109, developed by the US biotechnology company Apnimed , consists of the marketed drug atomoxetine and a novel isomer, R -oxybutynin , derived from the older drug oxybutynin. It works by modulating nerve signals, allowing patients to maintain airway tone during sleep and reducing the occurrence of sleep apnea. Its new drug application ...
- Source: drugdu
- 71
- September 3, 2026
Biosimilar Export Accelerates! Jianyou’s Adalimumab Receives FDA Approval for Additional Manufacturing Site | Overseas Expansion News

On September 1, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (Jianyou, 603707.SH) announced that its subsidiary, Emerge Bioscience Pte. Ltd., recently received a letter from the U.S. Food and Drug Administration (FDA) approving an additional manufacturing site for adalimumab injection (40 mg/0.8 mL, single-dose) under BLA No. 761216. The approval authorizes production at the Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. facility. Adalimumab injection, a biosimilar, was first approved by the U.S. FDA on December 17, 2021. Its indications cover multiple autoimmune diseases including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. The approval of the additional Nanjing manufacturing site further strengthens the product’s supply chain capabilities, providing more stable supply assurance for the U.S. market. Jianyou is an integrated pharmaceutical group focusing on R&D, production, and sales, with core business centered on heparin API and formulation supply. It has over 80 ...
- Source: drugdu
- 75
- September 3, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.